$Altimmune (ALT.US)$Altimmune Presents Data From Its Phase 2, MRI-Based Body Composition Sub-study Of Pemvidutide In Subjects With Overweight And Obesity Benzinga· 1 min ago In an MRI sub-study of 67 subjects from the Phase 2 MOMENTUM obesity trial, 50 of whom were treated with pemvidutide for 48 weeks, the lean loss ratio, defined as the change in lean mass compared to the change in total mass, was 21.9%. Lean mass preservation was greater in subjects aged 60 years and older, in whom the ...
Altimmune股票讨论
更大的图像: tradingview.com...
$Altimmune (ALT.US)$
AI自动交易平台窗口
1号窗口:多空量化指标数值,美东实时时间
2号窗口:涨幅最大7个股票
3号窗口:板块指数ETF
4号窗口:实时时间和总盈亏金额
5号窗口:妖股从底部反弹排行榜 【建议买入妖股】
6号窗口:妖股创新高刷屏
7号窗口:妖股创新低刷屏
8号窗口:成长股从底部反弹排行榜 【建议买入成长股】
9号窗口:成长股创新高刷屏
10号窗口:成长股创新低刷屏
11号窗口:妖股瞬时上涨刷屏
12号窗口:扫描仪新股
13号窗口:Reddit热门关键字
14号窗口:扫描股实时新闻及AI评级
15号窗口:AI交易订单信息
16号窗口:妖股瞬时下跌刷...
Benzinga· 1 min ago
In an MRI sub-study of 67 subjects from the Phase 2 MOMENTUM obesity trial, 50 of whom were treated with pemvidutide for 48 weeks, the lean loss ratio, defined as the change in lean mass compared to the change in total mass, was 21.9%.
Lean mass preservation was greater in subjects aged 60 years and older, in whom the ...
altimmune在第60届欧洲糖尿病研究协会年会上发布了第2期基于MRI的体成分子研究结果
altimmune在第60届欧洲糖尿病研究协会年会上展示了pemvidutide的第2期基于MRI的体成分子研究结果。这项研究涉及来自MOMENTUm肥胖试验的67名受试者,显示出pemvidutide,一种新型的GLP-1/胰高血糖素双受体激动剂,有希望的结果...
较大图像: tradingview.com...
$Altimmune (ALT.US)$
$Altimmune (ALT.US)$
更大的图像: tradingview.com...
$Altimmune (ALT.US)$
较大图像: tradingview.com...
$Altimmune (ALT.US)$
暂无评论